Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. (15th December 2021)

• Record Type: Journal Article
• Authors: Cao, Dujuan; Song, Qianqian; Li, Junqi; Jiang, Yuanyuan; Wang, Zhimin; Lu, Shuangshuang
• Is Part Of: Expert reviews in molecular medicine. Volume 23(2021)
• Publication Date: 2021-12-15
• Subjects: clinical trial -- immunotherapy -- pancreatic cancer -- targeted therapy; Molecular biology -- Periodicals; 616.042
• DOI: 10.1017/erm.2021.26
• Languages: English
• ISSNs: 1462-3994

Abstract

Abstract: Pancreatic cancer is one of the most malignant tumours with a poor prognosis. In recent years, the incidence of pancreatic cancer is on the rise. Traditional chemotherapy and radiotherapy for pancreatic cancer have been improved, first-line and second-line palliative treatments have been developed, and adjuvant treatments have also been used in clinical. However, the 5-year survival rate is still less than 10% and new treatment methods such as targeted therapy and immunotherapy need to be investigated. In the past decades, many clinical trials of targeted therapies and immunotherapies for pancreatic cancer were launched and some of them showed an ideal prospect in a subgroup of pancreatic cancer patients. The experience of both success and failure of these clinical trials will be helpful to improve these therapies in the future. Therefore, the current research progress and challenges of selected targeted therapies and immunotherapies for pancreatic cancer are reviewed.